Meeting Banner
Abstract #1425

Impact of Scanner Heterogeneity on a Multi-Center Trial

Ken Sakaie1, Paola Raska2, Nancy Obuchowski2, Kunio Nakamura3, Mark J. Lowe1, and Robert J. Fox4
1Imaging Institute, The Cleveland Clinic, Cleveland, OH, United States, 2Quantitative Health Sciences, The Cleveland Clinic, Cleveland, OH, United States, 3Lerner Research Institute, The Cleveland Clinic, Cleveland, OH, United States, 4Neurological Institute, The Cleveland Clinic, Cleveland, OH, United States

In a clinical trial, it may be necessary to incorporate multiple centers to get a sufficiently large sample size. Trials that use imaging may suffer from heterogeneity among centers in terms of scanner platform. In the SPRINT-MS trial, diffusion tensor imaging (DTI) measures indicated a larger treatment effect than brain parenchymal fraction (BPF). However, the effect measured by DTI was not statistically significant. In this study, we examine the hypothesis that heterogeneity in scanner type contributed to variance in DTI measures, reducing the statistical power of the measurement.

This abstract and the presentation materials are available to 2020 meeting attendees and eLibrary customers only; a login is required.

Join Here